STOCK TITAN

Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 12, 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Champions Oncology, Inc. (CSBR) will release its Q3 financial and operational results on March 12, 2024, followed by a conference call. The call will discuss the company's performance and future outlook.
Positive
  • None.
Negative
  • None.

HACKENSACK, NJ / ACCESSWIRE / March 6, 2024 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the third quarter ended January 31, 2024, on Tuesday, March 12, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 877-545-0523 (Domestic) or 973-528-0016 (International) and enter the access code 860900. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 50100, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.

Media Contact:
Rachel Bunting, MS, MBA
VP, Global Marketing
Marketing@ChampionsOncology.com

Website: www.championsoncology.com
Facebook: www.facebook.com/championsoncology/
LinkedIn: www.linkedin.com/company/champions-oncology-inc-/
Twitter: www.twitter.com/ChampionsOncol1
Instagram: www.instagram.com/championsoncology/

SOURCE: Champions Oncology, Inc.



View the original press release on accesswire.com

FAQ

When will Champions Oncology (CSBR) release its Q3 financial and operational results?

Champions Oncology (CSBR) will release its Q3 financial and operational results on March 12, 2024.

What time is the conference call to discuss the results?

The conference call to discuss the results will be held at 4:30 P.M. EDT (1:30 P.M. PDT) on March 12, 2024.

How can I join the conference call?

To join the conference call, dial 877-545-0523 (Domestic) or 973-528-0016 (International) and enter the access code 860900.

Will there be a replay of the conference call available?

Yes, a replay of the conference call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 50100, or by accessing the investors section of the company's website within 72 hours.

Champions Oncology, Inc.

NASDAQ:CSBR

CSBR Rankings

CSBR Latest News

CSBR Stock Data

63.89M
4.72M
25.56%
42.15%
0.43%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
BALTIMORE

About CSBR

champions oncology, inc. is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs. champions tumorgraft™ technology platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments, or tumorgrafts, in a manner that preserves the biological characteristics of the original human tumor. champions believes that these tumorgrafts, unlike cell line derived xenografts used in tradition testing, closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. the company offers personalized tumorgraft development, drug studies and genome sequencing as part of its personalized oncology solutions ("pos") whereby physicians can evaluate the effects of cancer drugs on their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them